TreatSMA

TreatSMA release Community Statement on the current Covid-19 Pandemic

TreatSMA have today released a community statement with regards to the current lack of information for a vulnerable community.

Please read the statement released by TreatSMA below regarding the current coronavirus outbreak and where we stand as a charity, advocates and representatives for the UK SMA community and what we feel should be happening.

We feel that yet again we have been left to fend for ourselves and have not been issued any guidance that is suitable and relevant to SMA individuals and families lives, with no one reaching out to support or offer advice to our anxious community.

There seems to be a total lack of action in the UK compared to other nations who are taking responsible and immediate action to control the spread.

We have again sent this to all press contacts, and we await the outcome of today’s emergency Cobra meeting, where we hope there will be better guidance issued to protect our community.

We at TreatSMA are always here to support our community.

Loader Loading…
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download the document [90.60 KB]

Regards

The TreatSMA Team

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more